Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.74 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.66 |
| ▸ | USP1 | O94782 | 1/20 | 0.61 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2395193 | 0.99 | APP (0.73) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3977315 | 0.87 | RAD52 (0.71) | APPEGFRNR2F2LMNATSHR | |
| SCHEMBL3118894 | 0.86 | APP (0.74) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL2586993 | 0.86 | SLC2A1 (0.81) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL2255109 | 0.86 | SLC2A1 (0.81) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL12175936 | 0.86 | APP (0.74) | APPLMNATSHRALDH1A1HTT | |
| SCHEMBL4867976 | 0.86 | APP (0.76) | APPSLC2A1EGFRLMNATP53 | |
| Hydrochloric Acid SCHEMBL3640013 | 0.85 | SLC2A1 (0.80) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3121699 | 0.85 | APP (0.73) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL2256525 | 0.85 | APP (1.00) | APPSLC2A1POLBEGFRNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261739-A1 | Method of Treating Non-Small Cell Lung Cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20100137342-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20100093773-A1 | METHODS OF TREATING CANCER | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20100087458-A1 | METHOD OF TREATING MELANOMA | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | US | claimed |
| US-20100087457-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | Myriad Pharmaceuticals, Inc (US) | 2010-04-08 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-03-12 | — | — | US | claimed |
| WO-2009023876-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER | MYRIAD GENETICS, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1890677-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-11-08 | — | — | US | claimed |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006138608-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100261739-A1 | Method of Treating Non-Small Cell Lung Cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100087457-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | Myriad Pharmaceuticals, Inc (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2144886-A1 | METHOD OF TREATING MELANOMA | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144888-A1 | METHODS FOR TREATING CANCER | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144886-A1 | METHOD OF TREATING MELANOMA | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144504-A1 | METHOD OF TREATING BRAIN CANCER | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144504-A1 | METHOD OF TREATING BRAIN CANCER | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144887-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144888-A1 | METHODS FOR TREATING CANCER | Myriad Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023876-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER | MYRIAD GENETICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008124823-A1 | METHOD OF TREATING MELANOMA | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124826-A1 | METHODS FOR TREATING CANCER | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124826-A1 | METHODS FOR TREATING CANCER | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124822-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124828-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124823-A1 | METHOD OF TREATING MELANOMA | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124822-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124824-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124828-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1890677-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006138608-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | APP 1620/4885SLC2A1 1031/4885POLB 3869/4885 |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | APP 2989/4885SLC2A1 2605/4885POLB 1857/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3261/4885SLC2A1 2886/4885POLB 1789/4885 |
| US-20100137342-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | VEGFA, FLT4, PDE3A | APP 4605/4885SLC2A1 1972/4885POLB 1603/4885 |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | APP 1620/4885SLC2A1 1031/4885POLB 3869/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | APP 1620/4885SLC2A1 1031/4885POLB 3869/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20100261739-A1 | Method of Treating Non-Small Cell Lung Cancer | TUBB3, NES, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | APP 4740/4885SLC2A1 2882/4885POLB 3201/4885 |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | APP 1620/4885SLC2A1 1031/4885POLB 3869/4885 |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | APP 4386/4885SLC2A1 21/4885POLB 4499/4885 |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3339/4885SLC2A1 2881/4885POLB 1890/4885 |
| US-20100087457-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, INMT | APP 4350/4885SLC2A1 1412/4885POLB 2447/4885 |
| US-20100093773-A1 | METHODS OF TREATING CANCER | TOP2A, VHL, TOP2B | APP 4876/4885SLC2A1 920/4885POLB 453/4885 |
| US-20100087458-A1 | METHOD OF TREATING MELANOMA | TYR, HNMT, PNMT | APP 4862/4885SLC2A1 1681/4885POLB 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.